Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $91.55.

Several research firms have commented on RARE. Wedbush raised their price objective on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a "neutral" rating in a research report on Friday, February 16th. JPMorgan Chase & Co. raised their target price on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an "overweight" rating in a report on Monday, March 18th. Cantor Fitzgerald reissued an "overweight" rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday. Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a "buy" rating in a research report on Wednesday, February 21st. Finally, Robert W. Baird upped their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, January 30th.

Ultragenyx Pharmaceutical Trading Up 0.7 %

NASDAQ:RARE traded up $0.33 on Tuesday, hitting $50.56. 530,495 shares of the stock were exchanged, compared to its average volume of 752,568. Ultragenyx Pharmaceutical has a fifty-two week low of $31.52 and a fifty-two week high of $54.98. The stock has a fifty day moving average of $47.90 and a 200-day moving average of $43.06. The stock has a market cap of $4.16 billion, a PE ratio of -6.07 and a beta of 0.65.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.65) by $0.13. The company had revenue of $127.39 million during the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The business's quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.16) earnings per share. As a group, analysts predict that Ultragenyx Pharmaceutical will post -6.34 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Thomas Richard Kassberg sold 11,509 shares of the company's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the sale, the executive vice president now owns 252,823 shares in the company, valued at approximately $12,623,452.39. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the sale, the director now owns 14,860 shares of the company's stock, valued at $756,076.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas Richard Kassberg sold 11,509 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the transaction, the executive vice president now owns 252,823 shares in the company, valued at $12,623,452.39. The disclosure for this sale can be found here. Insiders sold 31,974 shares of company stock worth $1,639,721 in the last quarter. 6.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently made changes to their positions in RARE. Sands Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $123,335,000. RTW Investments LP lifted its position in Ultragenyx Pharmaceutical by 27.4% during the 4th quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company's stock worth $329,340,000 after buying an additional 1,481,997 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company's stock valued at $414,764,000 after purchasing an additional 1,440,264 shares in the last quarter. Norges Bank bought a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $36,846,000. Finally, BlackRock Inc. lifted its holdings in Ultragenyx Pharmaceutical by 12.4% during the 1st quarter. BlackRock Inc. now owns 4,873,356 shares of the biopharmaceutical company's stock worth $195,422,000 after buying an additional 536,513 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.